88 related articles for article (PubMed ID: 23128116)
1. A defect in vasopressin secretion in autosomal dominant polycystic kidney disease.
Bichet DG
Kidney Int; 2012 Nov; 82(10):1051-3. PubMed ID: 23128116
[TBL] [Abstract][Full Text] [Related]
2. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.
Ho TA; Godefroid N; Gruzon D; Haymann JP; Maréchal C; Wang X; Serra A; Pirson Y; Devuyst O
Kidney Int; 2012 Nov; 82(10):1121-9. PubMed ID: 22718190
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
4. [Clinical, genetic and molecular studies on autosomal dominant polycystic kidney disease].
Torra R; Badenas C; Darnell A; Nicolau C; Volpini V; Revert L; Estivill X
Med Clin (Barc); 1998 Apr; 110(13):481-7. PubMed ID: 9611728
[TBL] [Abstract][Full Text] [Related]
5. [Genetic analysis (PKD2) of autosomal dominant polycystic kidney disease].
Gómez PF; Moro EC; García-Cosmes P; Sarmiento RG; Romo JM
Nefrologia; 2009; 29(6):562-8. PubMed ID: 19936001
[TBL] [Abstract][Full Text] [Related]
6. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
Noël N; Rieu P
Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
[TBL] [Abstract][Full Text] [Related]
7. Autosomal recessive and dominant polycystic kidney diseases.
Sessa A; Righetti M; Battini G
Minerva Urol Nefrol; 2004 Dec; 56(4):329-38. PubMed ID: 15785425
[TBL] [Abstract][Full Text] [Related]
8. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
9. Role of vasopressin antagonists.
Torres VE
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
[TBL] [Abstract][Full Text] [Related]
10. [Mutational analysis of the PKD1 and PKD2 (type 1 and 2 dominant autosomal polycystic kidney) genes].
Torra R; Badenas C; Pérez-Oller L; San Millán JL; Tellería D; Estivill X; Darnell A
Nefrologia; 2000; 20(1):39-46. PubMed ID: 10822721
[TBL] [Abstract][Full Text] [Related]
11. PKDB: Polycystic Kidney Disease Mutation Database--a gene variant database for autosomal dominant polycystic kidney disease.
Gout AM; Martin NC; Brown AF; Ravine D
Hum Mutat; 2007 Jul; 28(7):654-9. PubMed ID: 17370309
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of autosomal dominant polycystic kidney disease genes in Han Chinese.
Zhang S; Mei C; Zhang D; Dai B; Tang B; Sun T; Zhao H; Zhou Y; Li L; Wu Y; Wang W; Shen X; Song J
Nephron Exp Nephrol; 2005; 100(2):e63-76. PubMed ID: 15775720
[TBL] [Abstract][Full Text] [Related]
13. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease.
Chang MY; Parker E; El Nahas M; Haylor JL; Ong AC
J Am Soc Nephrol; 2007 Feb; 18(2):560-9. PubMed ID: 17202412
[TBL] [Abstract][Full Text] [Related]
14. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
[TBL] [Abstract][Full Text] [Related]
15. Novel PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease (ADPKD).
Hoefele J; Mayer K; Scholz M; Klein HG
Nephrol Dial Transplant; 2011 Jul; 26(7):2181-8. PubMed ID: 21115670
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
Masoumi A; Elhassan E; Schrier RW
Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
[TBL] [Abstract][Full Text] [Related]
17. Genotypes of autosomal dominant polycystic kidney disease in Japanese.
Mizoguchi M; Tamura T; Yamaki A; Higashihara E; Shimizu Y
J Hum Genet; 2002; 47(1):51-4. PubMed ID: 11829141
[TBL] [Abstract][Full Text] [Related]
18. PKD1 and PKD2 mutations in Slovenian families with autosomal dominant polycystic kidney disease.
Vouk K; Strmecki L; Stekrova J; Reiterova J; Bidovec M; Hudler P; Kenig A; Jereb S; Zupanic-Pajnic I; Balazic J; Haarpaintner G; Leskovar B; Adamlje A; Skoflic A; Dovc R; Hojs R; Komel R
BMC Med Genet; 2006 Jan; 7():6. PubMed ID: 16430766
[TBL] [Abstract][Full Text] [Related]
19. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
20. Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population.
Mannix C; Rangan A; Wong A; Zhang J; Allman-Farinelli M; Rangan G
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
